#Biosimilars #Jordan #Amman #MS Pharma #Hetero

MS Pharma Group Expands Biosimilar Access through Hetero Partnership

MS Pharma Group, a prominent player in the MENA pharmaceutical industry, has entered into a crucial partnership with Hetero Group, a renowned global pharmaceutical entity. This alliance aims to enhance the accessibility of biosimilars within the region, particularly focusing on oncological, immunological, and hematological therapies. This collaboration is set to make significant strides in localizing five well-established biosimilars.

This exclusive agreement will be executed via El Kendi, an affiliate of MS Pharma Group located in Algeria, and Hetero Biopharma, a subsidiary of the Hetero Group. Notably, this marks Hetero's inaugural local partnership in Algeria, symbolizing a leap towards fortifying Algeria's burgeoning biopharmaceutical landscape. The projected market valuation for the combined portfolio is estimated to reach USD 45 million by 2024 in Algeria. The plan emphasizes a localization and technology transfer approach aimed at maximizing the potential of local production, thereby ensuring enhanced local accessibility to these critical medications.

Kalle Känd, the CEO of MS Pharma, expressed enthusiasm over the collaboration, stating, "We are delighted to work with a globally recognized partner like Hetero. Our joint mission underscores a long-standing dedication to transferring knowledge and improving health outcomes for patients across the region. This partnership perfectly aligns with MS Pharma Group's objectives of broadening access to reliable and affordable biologic therapies, while fostering the sustainability and resilience of local health systems. Strategic collaborations such as this position us to cultivate persistent regional capacities that yield meaningful, lasting influences on patients and healthcare systems throughout the MENA region."

Dr. Vamsi Krishna, MD of Hetero Group, echoed similar sentiments, emphasizing their commitment to advancing patient access to quality affordable medicines globally. He remarked, "The partnership with MS Pharma represents a significant milestone in enhancing healthcare delivery and addressing unmet medical needs across the Middle East, Algeria, and other important markets. We anticipate that this collaboration will serve as a vital conduit in ensuring patients receive the necessary treatments they deserve."

MS Pharma Group has established itself as a preeminent pharmaceutical enterprise specializing in generic and biologic therapies across the MENA region. The company is agile and poised for rapid growth, operating five manufacturing facilities in Jordan, Algeria, and Saudi Arabia, including a recently inaugurated biologics plant, all catering to the expansive MENA marketplace. With its headquarters in Amman, Jordan, and management offices in Zug, Switzerland, MS Pharma is backed by a workforce exceeding 2,000 personnel across 12 nations.

Founded in Hyderabad, India, Hetero Group is recognized as one of the world leaders in the manufacturing of active pharmaceutical ingredients and generic formulations. The company is driven by a commitment to improving health outcomes worldwide through the provision of high-quality, affordable therapeutic options. Through its subsidiary Hetero Biopharma, the company is a pivotal player in the development of biosimilars, striving to broaden access to essential treatments through extensive research, manufacturing, and marketing efforts that span global markets.

As this partnership unfolds, the potential for improved patient care in the MENA region appears promising, paving the way for comprehensive healthcare solutions that address both immediate needs and long-term sustainability in the biopharmaceutical landscape.